Drug Eluting Balloon Market Report
First published: 11 October 2024 | Last updated: 25 May 2026 | Report Code: drug-eluting-balloon
Drug Eluting Balloon Market — USD 3.5 billion in 2023, Growing to USD 6.88B by 2033 at 6.8% CAGR
This report provides a detailed analysis of the Drug Eluting Balloon market from 2023 to 2033, including insights on market size, growth trends, regional analysis, and key players within the industry.
Key Takeaways
- Global market expands from $3.50 Billion in 2023 to $6.88 Billion by 2033 at a 6.8% CAGR.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- Europe rises from $1.01 Billion in 2023 to $1.98 Billion in 2033, reflecting sustained demand.
- Asia Pacific grows from $0.69 Billion in 2023 to $1.36 Billion in 2033 driven by procedure adoption.
- Top industry participants include Medtronic, Boston Scientific, C. R. Bard (part of BD), Abbott Laboratories, and Cook Medical.
Drug Eluting Balloon Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. This report examines the Drug Eluting Balloon market’s trajectory from 2023 to 2033, when global value is expected to reach $6.88 Billion from $3.50 Billion in 2023 at a 6.8% CAGR. Expansion is supported by technological improvements in balloon coatings and drug delivery, broader clinical use in coronary and peripheral interventions, and a shift toward minimally invasive procedures. Market structure is explored across device types, applications, materials, and end-users, with hospitals, ambulatory surgery centers, and clinics profiled. Regional breakdowns document North America as the largest market and present growth patterns for Europe, Asia Pacific, Latin America, and Middle East & Africa. Competitive positioning highlights established suppliers such as Medtronic and Boston Scientific, while research methodology combines expert interviews and secondary sources to validate trends.
Key Growth Drivers
- Advances in drug-coating and delivery technologies enhancing procedural outcomes.
- Rising use of less invasive vascular interventions across clinical settings.
- Growing incidence of vascular conditions increasing demand for effective interventions.
- Broader adoption in hospitals and ambulatory surgery centers supporting volume growth.
- Ongoing clinical validation and regulatory approvals enabling market entry and expansion.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $3.50 Billion |
| CAGR (2023-2033) | 6.8% |
| 2033 Market Size | $6.88 Billion |
| Top Companies | Medtronic , Boston Scientific, C. R. Bard (part of BD), Abbott Laboratories, Cook Medical |
| Published Date | 11 October 2024 |
| Last Modified Date | 25 May 2026 |
Drug Eluting Balloon Market Overview
Customize Drug Eluting Balloon Market Report market research report
- ✔ Get in-depth analysis of Drug Eluting Balloon market size, growth, and forecasts.
- ✔ Understand Drug Eluting Balloon's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Drug Eluting Balloon
What is the Market Size & CAGR of Drug Eluting Balloon Market Report market in 2023?
Drug Eluting Balloon Industry Analysis
Drug Eluting Balloon Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Drug Eluting Balloon Market Report Market Analysis Report by Region
Europe Drug Eluting Balloon Market Report:
Europe grows from $1.01 Billion in 2023 to $1.98 Billion in 2033. Regional expansion reflects increasing utilization of drug-eluting balloons in coronary and peripheral procedures and steady clinical validation across healthcare systems.Asia Pacific Drug Eluting Balloon Market Report:
Asia Pacific grows from $0.69 Billion in 2023 to $1.36 Billion in 2033. 69 Billion in 2023 and reaches $1.36 Billion by 2033. Growth drivers include rising procedure adoption, expanding access to interventional care, and increased demand for less invasive treatment options.North America Drug Eluting Balloon Market Report:
North America is largest regional market, rising from $1.17 Billion in 2023 to $2.3 Billion in 2033. 17 Billion in 2023, rising to $2.3 Billion in 2033. The region is identified as the largest market, supported by established interventional cardiology infrastructure, high procedural volumes, and adoption of new device technologies.South America Drug Eluting Balloon Market Report:
Latin America grows from $0.19 Billion in 2023 to $0.37 Billion in 2033. 19 Billion in 2023, increasing to $0.37 Billion in 2033. Market development is influenced by improved access to vascular interventions and growing clinical adoption in key treatment centers.Middle East & Africa Drug Eluting Balloon Market Report:
Middle East and Africa grows from $0.44 Billion in 2023 to $0.86 Billion in 2033. 44 Billion in 2023 and is projected to grow to $0.86 Billion by 2033. Expansion is driven by greater availability of interventional services and rising focus on advanced vascular therapies.Tell us your focus area and get a customized research report.
Research Methodology
Drug Eluting Balloon Market Analysis By Device Type
In 2023, the market for Drug Eluting Balloons segmented by device type shows a strong inclination towards coronary drug-eluting balloons, expected to grow from USD 2.14 billion to USD 4.21 billion by 2033, capturing 61.15% of the market share consistently over the years. Peripheral drug-eluting balloons hold a significant market position as well, with forecasts indicating growth from USD 0.83 billion to USD 1.64 billion, making up 23.85% of the market.
Drug Eluting Balloon Market Analysis By Application
The application-based segmentation reveals that coronary artery disease treatment remains the dominant segment, projected to account for a majority market share. Peripheral artery disease applications are also crucial, anticipated to grow significantly in both size and share, underlining the importance of diverse medical needs met by drug-eluting balloons.
Drug Eluting Balloon Market Analysis By End User
Hospitals remain the largest end-user segment, with market size expected to rise from USD 2.14 billion to USD 4.21 billion. They contribute to 61.15% of the market share, followed closely by ambulatory surgery centers and clinics, each catering to the scaling demand for outpatient and minimally invasive procedures.
Drug Eluting Balloon Market Analysis By Material
The segmentation by material indicates a significant market for polymeric materials, which are expected to dominate in both size and share. Currently, they represent 61.15% of the market, while metallic and composite materials possess a smaller, yet relevant, share, highlighting innovations in material science affecting product performance and patient outcomes.
Drug Eluting Balloon Market Analysis By Region
Regionally, North America holds the largest market share while Europe and Asia-Pacific are rapidly growing segments. The rest of the world, particularly South America and the Middle East, are emerging markets showcasing substantial growth opportunities due to increasing healthcare investments and improved distribution channels.
Drug Eluting Balloon Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Drug Eluting Balloon Industry
Medtronic :
Medtronic is a leading player in the medical devices sector, offering innovative drug-eluting balloons aimed at treating coronary artery disease with proven efficacy and safety profiles.Boston Scientific:
Boston Scientific is renowned for its cutting-edge medical solutions, focusing extensively on developing advanced drug-eluting balloon technologies to improve patient outcomes in cardiovascular therapy.C. R. Bard (part of BD):
With a long legacy in vascular intervention, C. R. Bard integrates drug-eluting technology into their balloon intervention products, addressing critical needs in peripheral artery disease management.Abbott Laboratories:
Abbott maintains a significant presence in the drug-eluting balloon market through its innovative products that enhance the treatment landscape of cardiovascular diseases.Cook Medical:
Cook Medical focuses on providing innovative solutions in the vascular sector, including drug-eluting balloons that cater to complex interventional needs.We're grateful to work with incredible clients.
FAQs
What is the market size of the Drug Eluting Balloon market in 2023?
The market size in 2023 is $3.50 Billion, as specified in the report's base year data for the 2023 to 2033 forecast period.
How big will the Drug Eluting Balloon market be in 2033?
By 2033 the market is projected to reach $6.88 Billion according to the provided forecast figures for the 2023 to 2033 period.
What is CAGR for the forecast period?
The compound annual growth rate for the forecast period 2023 to 2033 is 6.8%, based on the market progression from 2023 to 2033.
Is there a single fastest Growing region in the Drug Eluting Balloon Market Report market?
No single fastest-growing region is stated for the Drug Eluting Balloon Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
Which companies lead the Drug Eluting Balloon market?
Top companies listed include Medtronic, Boston Scientific, C. R. Bard (part of BD), Abbott Laboratories, and Cook Medical as key market participants.
What applications drive demand for these devices?
Primary applications include angioplasty and peripheral artery disease treatments, which drive procedural demand across hospitals and outpatient settings.
How big is the Europe market in 2023 and 2033?
Europe is reported at $1.01 Billion in 2023 and is expected to grow to $1.98 Billion by 2033, per the regional figures provided.
What role do clinical validations play?
Clinical validations and regulatory approvals are critical for market entry and adoption, influencing competitive positioning and acceptance by clinicians.
Who are the primary end Users for drug eluting balloons?
Primary end-users specified are hospitals, ambulatory surgery centers, and clinics, reflecting settings where interventional procedures are performed.
What is the market size of Asia Pacific in 2023?
Asia Pacific is recorded at $0.69 Billion in 2023 and is forecast to reach $1.36 Billion by 2033 according to the regional data.